CDH Investments-backed Chinese biopharmaceutical firm Mabpharm has joined a list of biotech firms seeking to raise capital through a listing in Hong Kong, which recently relaxed rules to allow biotech companies with no revenue to go public.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
